NVS logo

Novartis AG (NVS)

$159.13

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on NVS

Market cap

$303.64B

EPS

7.15

P/E ratio

20.1

Price to sales

4.84

Dividend yield

2.999%

Beta

0.416947

Price on NVS

Previous close

$160.20

Today's open

$158.46

Day's range

$158.37 - $160.03

52 week range

$123.24 - $170.46

Profile about NVS

CEO

Vasant Narasimhan

Employees

75267

Headquarters

Basel,

Exchange

New York Stock Exchange

Shares outstanding

1.91B

Issue type

American Depository Receipt

NVS industries and sectors

Healthcare

Pharmaceuticals

News on NVS

NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica

Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.

news source

Zacks Investment Research • 4 hours ago

news preview

Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Basel, November 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.¹ Cosentyx is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for people living with PMR, a common inflammatory disease that primarily affects adults over 50, providing a new treatment option beyond long-term steroid use—the current standard of care, which may be associated with significant side effects and risks.¹⁻⁵

news source

GlobeNewsWire • Nov 17, 2026

news preview

Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS

NVS' Cosentyx gains a positive CHMP recommendation for adolescents with moderate to severe HS, potentially expanding treatment options in Europe.

news source

Zacks Investment Research • Nov 16, 2026

news preview

Is Novartis (NVS) Outperforming Other Medical Stocks This Year?

Here is how Novartis (NVS) and Alpha Cognition Inc. (ACOG) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Nov 16, 2026

news preview

Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice

Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

news source

Zacks Investment Research • Nov 12, 2026

news preview

A failed trial for a heart drug casts shadow over rivals developing similar therapies

The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.

news source

Market Watch • Nov 9, 2026

news preview

3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026

In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Novartis: 3 Key Takeaways for Long-Term Investors

Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.

news source

The Motley Fool • Nov 4, 2026

news preview

Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target

The recent failure of a Novartis experimental heart drug in a large trial raised questions among cardiologists and investors about the widely held idea tha

news source

Reuters • Nov 2, 2026

news preview

6 dividend stocks for investors who want to cut their exposure to the S&P 500

Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.

news source

Market Watch • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Novartis AG

Open an M1 investment account to buy and sell Novartis AG commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in NVS on M1